A Study of SPY002-072 in Healthy Volunteers

Launched by SPYRE THERAPEUTICS, INC. · Sep 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new drug called SPY002-072 to see how safe it is and how the body processes it. It's designed for healthy volunteers, which means it’s looking for people who do not have any significant health issues. The trial is currently recruiting participants aged 18 to 65, both men and women, who are willing to attend all necessary appointments and stay at the study site for a specific period.

Participants in this study will receive either the study drug or a placebo (which looks like the drug but has no effect) to compare the results. Before joining, individuals will need to meet certain criteria, such as not having any serious health problems, not having used drugs or alcohol excessively in the past three months, and not having a history of severe allergic reactions. Those who take part can expect to be monitored closely during their time in the study to ensure their safety. This study is a crucial step in understanding how SPY002-072 might be used in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy men and women
• • Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
• Exclusion Criteria:
• • Participation in more than one cohort
• • Evidence of clinically significant abnormality or disease
• • Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
• • History of severe allergic reactions or hypersensitivity
• • Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing